This gradual shift has raised concerns about the franchise's ability to withstand competitive pressures in the near term. Dupixent has emerged as a significant growth driver for Regeneron ...

In addressing the fourth-quarter figures for Eylea three weeks earlier at the J.P. Morgan Healthcare Conference, Regeneron had hoped to shift the focus of its quarterly call to positive news ...